Audit of the use of Omalizumab in Tayside

• Research type

  Research Study

• Full title

  Audit of the use of Omalizumab in Tayside

• IRAS ID

  161819

• Contact name

  Thomas Fardon

• Contact email

  tom.fardon@nhs.net

• Sponsor organisation

  University of Dundee

• Duration of Study in the UK

  0 years, 4 months, 17 days

• Research summary

  Patients on Omalizumab treatment should be followed up closely to monitor their response to the therapy, to justify ongoing treatment. Current follow up mechanisms are opportunistic, rather than systematic. The project aims to develop a database of Omalizumab therapy patients, with a full dataset of baseline, and ongoing measurements.
  The project aims to use the data collected in the database and analyse it in order to answer the following two research questions:
  • What proportions of our patients receive guideline recommended doses, and dosing intervals?
  • Do we stick to the published national guidelines when prescribing and continuing Omalizumab therapy?

• REC name

  North West - Greater Manchester West Research Ethics Committee

• REC reference

  14/NW/1494

• Date of REC Opinion

  9 Dec 2014

• REC opinion

  Favourable Opinion